Although PD-L1 expression in melanomas correlates with good response to PD-1 inhibitory therapy it is not strictly required with a significant proportion of patients responding to ICI despite the lack of detectable PD-L1 in their tumor tissue [21–23]. The gene discussed is PDCD1; the disease is melanoma.